|Click here for details on how to download this file |
HELP PREVENT SREs IN ADULT PATIENTS WITH BONE METASTASES FROM SOLID TUMOURS
• Bone métastasés affect many patients with advanced disease and often lead to SREs
• XGEVA is administered as a subcutaneous injection of 120mg once every 4 weeks
ESMO guidelines recommend starting a bone targeted agent, XGEVA or zoledronic acid:
• in all patients with metastatic breast cancer and bone métastasés, whether they are symptomatic or not
• in patients with advanced lung cancer, renal cancer and other solid tumours who have a life expectancy more than 3 months and are considered at high risk of SREs
PRECISE. PROVEN. PRACTICAL.
Other ads from this campaign
Country/Market: Ireland, Europe
Target: Healthcare Professional (HCP)
Tagline: Precise. Proven. Practical.
Size/duration: Single-page plus one-half of page
Oncology News - November / December 2015
See more Xgeva ads
|Rate this file (No vote yet)|